Table I. Frequency of targeted integration in HCT116 cells.
| HCT116 cells | Targeting construct | |||
|---|---|---|---|---|
| |
XRCC2-neo (%)a |
p value relative to parent |
RAD51L2-neo (%)a |
p value relative to parent |
| RAD54B+/+/+ | 6.4 (6/94) | – | 0.083 (6/7197) | – |
| RAD54B+/+/–p37 | 7.5 (7/93) | 0.49 | 0.101 (6/5948) | 0.48 |
| RAD54B+/–/–h9 | 8.4 (14/166) | 0.37 | 0.108 (7/6509) | 0.43 |
| RAD54B–/–/–b125 | 0.6 (1/173) | 8.5 × 10–3 | 0.010 (1/10382) | 2.1 × 10–2 |
| RAD54B–/–/–b140 | 0 (0/120) | 6.6 × 10–3 | 0 (0/7398) | 1.4 × 10–2 |
| RAD54B–/–/–b125 + RAD54B-zeo | 15.0 (3/20) | 0.95 | ND | ND |
aThe frequency of targeted integration is shown as a percentage of correctly targeted clones relative to the total number of drug-resistant clones analyzed; absolute numbers are given in parentheses. The difference in frequency between RAD54B–/–/–b125 and RAD54B–/–/–b125 + RAD54B-zeo for XRCC2-neo was statistically significant (p = 3.6 × 10–3). ND, not determined. p values were calculated using Fisher’s exact test.